2022
Statin Usage Increases White Matter Hyperintensities
Goldstein ED, Garg G, Navarro K, Wolcott Z, Yaghi S, Wong KH, McLean K, de Havenon AH. Statin Usage Increases White Matter Hyperintensities. The Neurologist 2022, 28: 94-98. PMID: 35680399, DOI: 10.1097/nrl.0000000000000448.Peer-Reviewed Original ResearchConceptsWhite matter hyperintensitiesWMH progressionStatin usageTop tertileRisk factorsMatter hyperintensitiesWMH volumeConventional cerebrovascular risk factorsProgression of WMHCerebral small vessel diseaseInfluence of dyslipidemiaCerebrovascular risk factorsInfluence of statinsBaseline WMH volumeSmall vessel diseaseSynergistic risk factorsLow-density lipoproteinFull therapyStatin useVessel diseaseStudy visitWMH developmentPartial therapyWMH dataReductase inhibitors
2019
Is There Equipoise Regarding the Optimal Medical Treatment of Patients with Asymptomatic White Matter Hyperintensities?
de Havenon A, Prabhakaran S, Turan T, Gottesman R, Yeatts S, Rost N. Is There Equipoise Regarding the Optimal Medical Treatment of Patients with Asymptomatic White Matter Hyperintensities? Journal Of Stroke And Cerebrovascular Diseases 2019, 28: 104371. PMID: 31495669, PMCID: PMC8015436, DOI: 10.1016/j.jstrokecerebrovasdis.2019.104371.Peer-Reviewed Original ResearchMeSH KeywordsAntihypertensive AgentsAsymptomatic DiseasesAttitude of Health PersonnelDisease ProgressionHealth Care SurveysHealth Knowledge, Attitudes, PracticeHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLeukoencephalopathiesNeurologistsPlatelet Aggregation InhibitorsPractice Patterns, Physicians'Therapeutic EquipoiseTreatment OutcomeConceptsAsymptomatic white matter hyperintensitiesWhite matter hyperintensitiesOptimal medical treatmentMatter hyperintensitiesMedical treatmentCognitive impairmentIntensive Blood Pressure ReductionNeurologists' attitudesBlood pressure targetsStroke prevention therapyBlood pressure reductionOptimal medical managementRegional coordinating centersMild cognitive impairmentStatin therapyIschemic strokeMicrovascular diseasePressure targetsPrevention therapyClinical outcomesFunctional disabilityMedical managementPatient populationCommon manifestationWMH progressionBlood pressure, glycemic control, and white matter hyperintensity progression in type 2 diabetics
de Havenon A, Majersik JJ, Tirschwell DL, McNally JS, Stoddard G, Rost NS. Blood pressure, glycemic control, and white matter hyperintensity progression in type 2 diabetics. Neurology 2019, 92: e1168-e1175. PMID: 30737332, PMCID: PMC6511110, DOI: 10.1212/wnl.0000000000007093.Peer-Reviewed Original ResearchConceptsType 2 diabeticsBlood pressureWhite matter hyperintensitiesRandomization armGlycemic controlWMH progressionHigher systolic blood pressureWhite matter hyperintensity progressionIntensive blood pressureBlood pressure controlSystolic blood pressureHigh blood pressureType 2 diabetesACCORD-MINDComorbid diabetesMacrovascular complicationsCardiovascular riskHemoglobin A1cPrimary outcomeControl armMatter hyperintensitiesAggressive approachWMH volumeControl interventionsPressure control